Also known as: Mounjaro · Zepbound · LY3298176
Tirzepatide (Mounjaro/Zepbound) is the first FDA-approved dual GIP/GLP-1 receptor agonist, developed by Eli Lilly. It produces superior weight loss (~21% at 72 weeks) and glycemic control versus any prior GLP-1 monotherapy, leveraging synergistic activation of both incretin receptors. Approved for T2D (2022) and obesity (2023).
Tirzepatide represents a paradigm shift from single-receptor GLP-1 agonism to dual incretin targeting. Developed by Eli Lilly using their "twincretin" platform, it is a single synthetic peptide molecule that activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors with high potency.
Its backbone is based on the native GIP sequence, modified at multiple positions to achieve balanced GIP/GLP-1 potency and enhanced metabolic stability. A C20 fatty diacid chain is conjugated via a linker to an internal lysine residue, enabling albumin binding that extends the half-life to approximately 5 days.
FDA approved in May 2022 as Mounjaro for type 2 diabetes management, and in November 2023 as Zepbound for chronic weight management. In the SURMOUNT-1 trial, tirzepatide 15 mg achieved 22.5% mean body weight reduction over 72 weeks — the highest reported for any approved pharmaceutical obesity treatment at the time.
Tirzepatide co-activates GIP-R and GLP-1R, producing effects that exceed GLP-1 monotherapy. GIP-R activation in adipose tissue directly enhances insulin-stimulated fat storage and lipolysis regulation. In the CNS, GIP-R activation reduces food intake through mechanisms distinct from GLP-1, producing additive appetite suppression.
In SURPASS trials, tirzepatide produced greater HbA1c reductions than semaglutide 1 mg (–2.46% vs –2.06% at 40 weeks in SURPASS-2) and all comparator agents. The GIP component is particularly important for post-prandial glucose control via potentiation of first-phase insulin secretion.
Body composition analyses show tirzepatide preferentially targets visceral fat over lean mass, with higher proportions of fat mass loss relative to lean mass compared to GLP-1 monotherapy.
Tirzepatide is superior to semaglutide for both weight loss and glycemic control based on head-to-head SURPASS-2 trial data. The GIP component appears to reduce the nausea burden relative to GLP-1 monotherapy — clinical experience suggests slightly better GI tolerability than equivalent doses of semaglutide. Same thyroid cancer class warning applies. Do not combine with other GLP-1/GIP agonists.
Like semaglutide, tirzepatide is designed for chronic ongoing use. SURMOUNT-4 trial showed ~14% weight regain within 1 year after stopping, underscoring the need for continued therapy in weight management. In T2D management, tirzepatide may allow reduction or elimination of other antidiabetic medications at maximal doses.
Same class warnings as semaglutide: avoid in MTC/MEN2 history. Pancreatitis risk. Avoid in pregnancy. Monitor thyroid by ultrasound if any nodules are detected. Do not use with insulin without physician supervision due to hypoglycemia risk.
SURPASS clinical trial program: Tirzepatide demonstrated superior glycemic and weight outcomes vs. semaglutide 1 mg, dulaglutide, and insulin glargine. SURPASS-2 head-to-head vs. semaglutide showed tirzepatide superiority on both HbA1c and body weight endpoints.
SURMOUNT obesity trials: 22.5% weight loss at 15 mg vs. 2.4% placebo (SURMOUNT-1). 15.7% weight loss in T2D patients (SURMOUNT-2).
Ask anything about Tirzepatide — mechanisms, dosing protocols, interactions, or research comparisons.
Semaglutide is an FDA-approved GLP-1 receptor agonist used for type 2 diabetes (Ozempic) and chronic weight management (…
AOD-9604 is a modified fragment of human growth hormone (hGH residues 177–191) with an added N-terminal tyrosine residue…
Cagrilintide (AM833) is a long-acting amylin analogue developed by Novo Nordisk. It mimics the satiety and gastric-empty…
MOTS-c is a 16-amino-acid mitochondria-derived peptide encoded within the 12S ribosomal RNA gene of the mitochondrial ge…